• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Transl Med . Complement augments antibody neutralization of SARS-CoV-2 variants

tetano

Editor, Senior Moderator
Sci Transl Med


. 2026 Jul 22;18(859):eaec6027.
doi: 10.1126/scitranslmed.aec6027. Epub 2026 Jul 22.
Complement augments antibody neutralization of SARS-CoV-2 variants

Martin Jungbauer-Groznica[SUP] 1 2 [/SUP], Pierre Rosenbaum[SUP] 3 [/SUP], Isabelle Staropoli[SUP] 2 [/SUP], Florence Guivel-Benhassine[SUP] 2 [/SUP], Pierre-Henri Commere[SUP] 4 [/SUP], Tom Perisse[SUP] 5 6 [/SUP], Lily Bruyère[SUP] 5 [/SUP], Aura Fantin Rengifo[SUP] 1 2 [/SUP], Alejandro De Cruz[SUP] 1 2 [/SUP], Andrea Cottignies-Calamarte[SUP] 1 2 [/SUP], Sabina Andreu[SUP] 1 2 7 [/SUP], Laurent Hocqueloux[SUP] 8 [/SUP], Thierry Prazuck[SUP] 8 [/SUP], Cyril Planchais[SUP] 3 [/SUP], Michael White[SUP] 9 [/SUP], Sophie Novault[SUP] 4 [/SUP], Sophie Trouillet-Assant[SUP] 5 6 [/SUP]; SEVARVIR investigators; Slim Fourati[SUP] 10 11 12 [/SUP], Nicolas de Prost[SUP] 10 11 13 14 [/SUP], Martin Killian[SUP] 5 15 [/SUP], Stéphane Paul[SUP] 5 16 [/SUP], Olivier Schwartz[SUP] 2 17 [/SUP], Hugo Mouquet[SUP] 3 [/SUP], Timothée Bruel[SUP] 1 2 17 [/SUP]; SEVARVIR Investigators


Collaborators, Affiliations
Abstract

The complement system is a major effector system of the humoral immune response, but its capacity to cooperate with antibodies to inhibit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a host remains poorly characterized. Here, we combined authentic virus neutralization, antibody engineering, and single viral particle analysis by flow virometry to show that complement enhances antibody neutralization of SARS-CoV-2. Addition of complement increased neutralization titers of sera from convalescent individuals (n = 14), vaccinated individuals (n = 15), and individuals with hybrid immunity (n = 15) against D614G, BA.1, XBB.1.5, and JN.1 variants by up to 42-fold. D614G and BA.1 displayed a high level of neutralization, which was only slightly improved by adding complement. Conversely, neutralization of XBB.1.5 and JN.1 was weak but strongly enhanced by complement. Among the 32 JN.1 nonneutralizers, 22 regained detectable neutralization in the presence of complement. The enhancement mainly relied on cross-reactive anti-S2 antibodies, but monoclonal antibodies targeting the receptor binding domain and N-terminal domain could also be augmented. Viral inhibition required antibody Fc hexamerization, C1q recruitment, and C3 deposition, but it was independent of the membrane attack complex formed by C9. Consistently, complement components were deposited at the surfaces of viral particles with no detectable virolysis. In sera from individuals with severe COVID-19, both complement-mediated neutralization and anti-S2 antibody levels were associated with improved survival. Overall, our data show that complement potentiates the ability of antispike antibodies to neutralize immune-evasive SARS-CoV-2 variants.


 
Back
Top